#BEGIN_DRUGCARD DB04387

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H19NO

# Chemical_IUPAC_Name:
(2S)-2-amino-3-cyclohexylpropan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1-Hydroxy-2-Amino-3-Cyclohexylpropane

# HET_ID:
CHA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C9H19NO/c10-9(7-11)6-8-4-2-1-3-5-8/h8-9,11H,1-7,10H2/t9-/m0/s1

# InChI_Key:
InChIKey=QWDRYURVUDZKSG-VIFPVBQESA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4387

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
157.2533

# Molecular_Weight_Mono:
157.146664235

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1EAG

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.56

# Predicted_LogS:
-1.7

# Predicted_Water_Solubility:
2.96e+00 g/l

# Primary_Accession_No:
DB04387

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
444569

# PubChem_Substance_ID:
46506482

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00905

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
N[C@H](CO)CC1CCCCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:16 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein. Membrane. Associated to membranes via binding to ATP6AP2

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
REN

# Drug_Target_1_GenBank_ID_Gene:
L00073

# Drug_Target_1_GenBank_ID_Protein:
190994

# Drug_Target_1_GeneCard_ID:
REN

# Drug_Target_1_Gene_Name:
REN

# Drug_Target_1_Gene_Sequence:
>1221 bp
ATGGATGGATGGAGAAGGATGCCTCGCTGGGGACTGCTGCTGCTGCTCTGGGGCTCCTGT
ACCTTTGGTCTCCCGACAGACACCACCACCTTTAAACGGATCTTCCTCAAGAGAATGCCC
TCAATCCGAGAAAGCCTGAAGGAACGAGGTGTGGACATGGCCAGGCTTGGTCCCGAGTGG
AGCCAACCCATGAAGAGGCTGACACTTGGCAACACCACCTCCTCCGTGATCCTCACCAAC
TACATGGACACCCAGTACTATGGCGAGATTGGCATCGGCACCCCACCCCAGACCTTCAAA
GTCGTCTTTGACACTGGTTCGTCCAATGTTTGGGTGCCCTCCTCCAAGTGCAGCCGTCTC
TACACTGCCTGTGTGTATCACAAGCTCTTCGATGCTTCGGATTCCTCCAGCTACAAGCAC
AATGGAACAGAACTCACCCTCCGCTATTCAACAGGGACAGTCAGTGGCTTTCTCAGCCAG
GACATCATCACCGTGGGTGGAATCACGGTGACACAGATGTTTGGAGAGGTCACGGAGATG
CCCGCCTTACCCTTCATGCTGGCCGAGTTTGATGGGGTTGTGGGCATGGGCTTCATTGAA
CAGGCCATTGGCAGGGTCACCCCTATCTTCGACAACATCATCTCCCAAGGGGTGCTAAAA
GAGGACGTCTTCTCTTTCTACTACAACAGAGATTCCGAGAATTCCCAATCGCTGGGAGGA
CAGATTGTGCTGGGAGGCAGCGACCCCCAGCATTACGAAGGGAATTTCCACTATATCAAC
CTCATCAAGACTGGTGTCTGGCAGATTCAAATGAAGGGGGTGTCTGTGGGGTCATCCACC
TTGCTCTGTGAAGACGGCTGCCTGGCATTGGTAGACACCGGTGCATCCTACATCTCAGGT
TCTACCAGCTCCATAGAGAAGCTCATGGAGGCCTTGGGAGCCAAGAAGAGGCTGTTTGAT
TATGTCGTGAAGTGTAACGAGGGCCCTACACTCCCCGACATCTCTTTCCACCTGGGAGGC
AAAGAATACACGCTCACCAGCGCGGACTATGTATTTCAGGAATCCTACAGTAGTAAAAAG
CTGTGCACACTGGCCATCCACGCCATGGATATCCCGCCACCCACTGGACCCACCTGGGCC
CTGGGGGCCACCTTCATCCGAAAGTTCTACACAGAGTTTGATCGGCGTAACAACCGCATT
GGCTTCGCCTTGGCCCGCTGA

# Drug_Target_1_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_1_General_References:
12045255	Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002 Jun;109(11):1417-27.
1608447	Dhanaraj V, Dealwis CG, Frazao C, Badasso M, Sibanda BL, Tickle IJ, Cooper JB, Driessen HP, Newman M, Aguilar C, et al.: X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature. 1992 Jun 11;357(6378):466-72.
2016271	Ishizuka Y, Shoda A, Yoshida S, Kawamura Y, Haraguchi K, Murakami K: Isolation and characterization of recombinant human prorenin in Chinese hamster ovary cells. J Biochem (Tokyo). 1991 Jan;109(1):30-5.
2493678	Sielecki AR, Hayakawa K, Fujinaga M, Murphy ME, Fraser M, Muir AK, Carilli CT, Lewicki JA, Baxter JD, James MN: Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science. 1989 Mar 10;243(4896):1346-51.
2540188	Burt DW, Nakamura N, Kelley P, Dzau VJ: Identification of negative and positive regulatory elements in the human renin gene. J Biol Chem. 1989 May 5;264(13):7357-62.
3032746	Fukamizu A, Nishi K, Nishimatsu S, Miyazaki H, Hirose S, Murakami K: Human renin gene of renin-secreting tumor. Gene. 1986;49(1):139-45.
3516796	Soubrier F, Panthier JJ, Houot AM, Rougeon F, Corvol P: Segmental homology between the promoter region of the human renin gene and the mouse ren1 and ren2 promoter regions. Gene. 1986;41(1):85-92.
3530608	Morris BJ: New possibilities for intracellular renin and inactive renin now that the structure of the human renin gene has been elucidated. Clin Sci (Lond). 1986 Oct;71(4):345-55.
6138751	Soubrier F, Panthier JJ, Corvol P, Rougeon F: Molecular cloning and nucleotide sequence of a human renin cDNA fragment. Nucleic Acids Res. 1983 Oct 25;11(20):7181-90.
6324167	Imai T, Miyazaki H, Hirose S, Hori H, Hayashi T, Kageyama R, Ohkubo H, Nakanishi S, Murakami K: Cloning and sequence analysis of cDNA for human renin precursor. Proc Natl Acad Sci U S A. 1983 Dec;80(24):7405-9.
6391881	Hardman JA, Hort YJ, Catanzaro DF, Tellam JT, Baxter JD, Morris BJ, Shine J: Primary structure of the human renin gene. DNA. 1984 Dec;3(6):457-68.

# Drug_Target_1_HGNC_ID:
HGNC:9958

# Drug_Target_1_HPRD_ID:
01564

# Drug_Target_1_ID:
298

# Drug_Target_1_Locus:
1q32

# Drug_Target_1_Molecular_Weight:
45058

# Drug_Target_1_Name:
Renin

# Drug_Target_1_Number_of_Residues:
406

# Drug_Target_1_PDB_ID:
1BBS

# Drug_Target_1_Pathway:
Benazepril Pathway	SMP00145
Captopril Pathway	SMP00146
Cilazapril Pathway	SMP00147
Enalapril Pathway	SMP00148
Fosinopril Pathway	SMP00149
Lisinopril Pathway	SMP00150
Moexipril Pathway	SMP00151
Perindopril Pathway	SMP00152
Quinapril Pathway	SMP00153
Ramipril Pathway	SMP00154
Rescinnamine Pathway	SMP00155
Spirapril Pathway	SMP00156
Trandolapril Pathway	SMP00157

# Drug_Target_1_Pfam_Domain_Function:
PF00026	Asp
PF07966	A1_Propeptide

# Drug_Target_1_Protein_Sequence:
>Renin precursor
MDGWRRMPRWGLLLLLWGSCTFGLPTDTTTFKRIFLKRMPSIRESLKERGVDMARLGPEW
SQPMKRLTLGNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRL
YTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEM
PALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGG
QIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISG
STSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKK
LCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR

# Drug_Target_1_Reaction:
Cleavage of Leu! bond in angiotensinogen to generate angiotensin I

# Drug_Target_1_Signals:
1-23

# Drug_Target_1_Specific_Function:
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney

# Drug_Target_1_SwissProt_ID:
P00797

# Drug_Target_1_SwissProt_Name:
RENI_HUMAN

# Drug_Target_1_Synonyms:
Angiotensinogenase
EC 3.4.23.15
Renin precursor

# Drug_Target_1_Theoretical_pI:
7.07

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M83663

# Drug_Target_2_GenBank_ID_Protein:
170841

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
SAP2

# Drug_Target_2_Gene_Sequence:
>1197 bp
ATGTTTTTAAAGAATATTTTCATTGCTCTTGCTATTGCTTTATTAGTCGATGCTACTCCA
ACAACAACCAAAAGATCAGCTGGTTTCGTTGCTTTAGATTTCAGTGTTGTGAAAACTCCT
AAAGCATTCCCAGTTACTAATGGTCAAGAAGGTAAAACTTCCAAAAGACAAGCTGTCCCA
GTGACTTTACACAATGAACAAGTCACTTATGCTGCTGATATTACCGTTGGATCCAATAAT
CAAAAACTTAATGTTATTGTTGATACTGGATCATCTGATTTATGGGTTCCTGATGTTAAT
GTTGATTGTCAAGTCACTTATAGTGATCAAACTGCAGATTTCTGTAAACAAAAGGGGACA
TATGATCCAAGTGGTTCATCAGCTTCACAAGATTTGAATACTCCATTCAAAATTGGTTAT
GGTGATGGATCTTCATCTCAAGGTACTTTATATAAGGATACCGTTGGATTTGGTGGTGTT
TCGATTAAAAATCAAGTTTTAGCTGATGTTGATTCTACTTCAATTGATCAAGGTATTTTA
GGAGTTGGTTATAAAACCAATGAAGCCGGTGGTAGTTATGATAATGTCCCTGTCACTTTA
AAAAAACAAGGAGTCATTGCTAAGAATGCTTATTCACTTTATCTTAATTCTCCAGATGCT
GCCACGGGACAAATAATTTTCGGTGGGGTTGATAATGCTAAATATAGTGGTTCATTAATT
GCATTACCAGTTACTTCTGATCGTGAATTAAGAATTAGTTTGGGTTCAGTTGAAGTTTCT
GGTAAAACCATCAATACTGATAATGTCGATGTTCTTTTGGATTCAGGTACCACCATTACT
TATTTGCAACAAGATCTTGCTGATCAAATCATTAAAGCTTTCAATGGTAAATTAACTCAA
GATTCCAATGGTAATTCATTCTATGAAGTTGATTGTAATTTGTCAGGGGATGTTGTATTC
AATTTTAGTAAAAATGCTAAAATTTCCGTTCCAGCTTCCGAATTTGCTGCTTCTTTACAA
GGTGATGATGGTCAACCATATGATAAATGTCAATTACTTTTCGATGTTAATGATGCTAAC
ATTCTTGGTGATAACTTTTTGAGATCAGCTTATATTGTTTATGATTTGGATGATAATGAA
ATTTCTTTGGCTCAAGTCAAATATACTTCTGCTTCCAGTATTTCTGCCTTGACCTAA

# Drug_Target_2_General_Function:
Involved in aspartic-type endopeptidase activity

# Drug_Target_2_General_References:
1447155	Wright RJ, Carne A, Hieber AD, Lamont IL, Emerson GW, Sullivan PA: A second gene for a secreted aspartate proteinase in Candida albicans. J Bacteriol. 1992 Dec;174(23):7848-53.
1491622	Mukai H, Takeda O, Asada K, Kato I, Murayama SY, Yamaguchi H: cDNA cloning of an aspartic proteinase secreted by Candida albicans. Microbiol Immunol. 1992;36(11):1207-16.
8407785	White TC, Miyasaki SH, Agabian N: Three distinct secreted aspartyl proteinases in Candida albicans. J Bacteriol. 1993 Oct;175(19):6126-33.
8591036	Cutfield SM, Dodson EJ, Anderson BF, Moody PC, Marshall CJ, Sullivan PA, Cutfield JF: The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure. 1995 Nov 15;3(11):1261-71.
9043112	Smolenski G, Sullivan PA, Cutfield SM, Cutfield JF: Analysis of secreted aspartic proteinases from Candida albicans: purification and characterization of individual Sap1, Sap2 and Sap3 isoenzymes. Microbiology. 1997 Feb;143 ( Pt 2):349-56.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
3180

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
42330

# Drug_Target_2_Name:
Candidapepsin-2

# Drug_Target_2_Number_of_Residues:
398

# Drug_Target_2_PDB_ID:
1EAG

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00026	Asp

# Drug_Target_2_Protein_Sequence:
>Candidapepsin-2 precursor
MFLKNIFIALAIALLVDATPTTTKRSAGFVALDFSVVKTPKAFPVTNGQEGKTSKRQAVP
VTLHNEQVTYAADITVGSNNQKLNVIVDTGSSDLWVPDVNVDCQVTYSDQTADFCKQKGT
YDPSGSSASQDLNTPFKIGYGDGSSSQGTLYKDTVGFGGVSIKNQVLADVDSTSIDQGIL
GVGYKTNEAGGSYDNVPVTLKKQGVIAKNAYSLYLNSPDAATGQIIFGGVDNAKYSGSLI
ALPVTSDRELRISLGSVEVSGKTINTDNVDVLLDSGTTITYLQQDLADQIIKAFNGKLTQ
DSNGNSFYEVDCNLSGDVVFNFSKNAKISVPASEFAASLQGDDGQPYDKCQLLFDVNDAN
ILGDNFLRSAYIVYDLDDNEISLAQVKYTSASSISALT

# Drug_Target_2_Reaction:
Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave Leu15-Tyr, Tyr16-Leu and Phe24-Phe of insulin B chain. Activates trypsinogen, and degrades keratin INHIBITOR Pepstatin

# Drug_Target_2_Signals:
1-18

# Drug_Target_2_Specific_Function:
Preferential cleavage at the carboxyl of hydrophobic amino acids, but fails to cleave 15-Leu-|-Tyr-16, 16- Tyr-|-Leu-17 and 24-Phe-|-Phe-25 of insulin B chain. Activates trypsinogen, and degrades keratin

# Drug_Target_2_SwissProt_ID:
P28871

# Drug_Target_2_SwissProt_Name:
CARP2_CANAL

# Drug_Target_2_Synonyms:
ACP 2
Aspartate protease 2
Candidapepsin-2 precursor
EC 3.4.23.24
Secreted aspartic protease 2

# Drug_Target_2_Theoretical_pI:
4.25

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04387
